首页> 美国卫生研究院文献>Cancer Management and Research >Real-world cost-effectiveness of targeted therapy in metastatic renal cell carcinoma in Sweden: a population-based retrospective analysis

【2h】

Real-world cost-effectiveness of targeted therapy in metastatic renal cell carcinoma in Sweden: a population-based retrospective analysis

机译：瑞典转移性肾细胞癌靶向治疗的现实成本效益：基于人群的回顾性分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

ObjectiveTo explore cost-effectiveness of targeted therapies (TTs) in the treatment of metastatic renal cell carcinoma (mRCC) in a real-world context using a nationwide population-based approach.

机译：目的探讨在全国范围内采用全国人群为基础的靶向治疗（TTs）在转移性肾细胞癌（mRCC）治疗中的成本效益。

著录项

期刊名称 Cancer Management and Research
作者
Josefine Redig; Johan Dalén; Ulrika Harmenberg; Magnus Lindskog; Börje Ljungberg; Sven Lundstam; Rickard Sandin; Thomas Wahlgren; Örjan Åkerborg; Maria Jakobsson;
展开▼
作者单位

展开▼
年(卷),期 2019(11),-1
年度 2019
页码 1289–1297
总页数 9
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
metastatic renal cell carcinoma targeted therapy cost-effectiveness Sweden;

机译：转移性肾细胞癌;靶向治疗;成本效益;瑞典;

相似文献

外文文献
中文文献
专利

1. International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study [J] . Ko Jenny J., Xie Wanling, Kroeger Nils, The lancet oncology . 2015,第3期

机译：国际转移性肾细胞癌数据库联合会模型作为先前接受过一线靶向治疗的转移性肾细胞癌患者的预后工具：一项基于人群的研究
2. Survival and clinical prognostic factors in metastatic non‐clear cell renal cell carcinoma treated with targeted therapy: A multi‐institutional, retrospective study using the Korean metastatic renal cell carcinoma registry [J] . Jung Kwon Kim, Sung Han Kim, Mi Kyung Song, Cancer Medicine . 2019,第7期

机译：靶向治疗治疗的转移性非透明细胞肾细胞癌的生存和临床预后因素：使用韩国转移性肾细胞癌登记系统的多机构回顾性研究
3. Real-World Effectiveness and Tolerability of Pazopanib as First Targeted Therapy in Metastatic Renal Cell Carcinoma: A Retrospective Chart Review in Latin America [J] . Muniz David Queiroz, Ratto Barbara, Yang Hongbo, Advances in therapy. . 2019,第12期

机译：Pazopanib的实际效力和耐受性作为转移性肾细胞癌的第一个靶向治疗：拉丁美洲的回顾性图表综述
4. When to Treat Metastatic Renal Cell Carcinoma Comorbidities, Systemic Therapy, and Active Surveillance in Metastatic Kidney Cancer [C] . Brian I. Rini Genitourinary Cancers Symposium . 2012

机译：何时治疗转移性肾细胞癌的组合，全身治疗，以及在转移性肾癌中的活跃监测
5. Methodological Approaches for Conducting Claims-Based Studies in Patients Diagnosed with Metastatic Renal Cell Carcinoma [D] . Chun, Danielle S. 2021

机译：用于诊断转移性肾细胞癌的患者的基于权利要求的基于权利要求的方法论方法
6. Survival prognoses of Heng intermediate-risk patients with metastatic renal cell carcinoma treated with immunotherapy or targeted therapy: A real-world single-center retrospective study [O] . Sung Han Kim, Dong-Eun Lee, Jae Young Joung, 2020

机译：免疫疗法或靶向疗法治疗的Heng中度转移性肾细胞癌患者的生存预后：一项真实的单中心回顾性研究
7. >Real-world cost-effectiveness of targeted therapy in metastatic renal cell carcinoma in Sweden: a population-based retrospective analysis [O] . Josefine Redig, Johan Dalén, Ulrika Harmenberg, 2019

机译：
瑞典转移性肾细胞癌的真实治疗成本效果：基于人口的回顾性分析

Real-world cost-effectiveness of targeted therapy in metastatic renal cell carcinoma in Sweden: a population-based retrospective analysis

摘要

著录项

相似文献

相关主题

期刊订阅